The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
August 17, 2015
Panobinostat (Farydak) for Multiple Myeloma (online only)
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Panobinostat (Farydak) for Multiple Myeloma (online only)
August 17, 2015 (Issue: 1475)
The FDA has approved panobinostat (Farydak –
Novartis), an oral histone deacetylase (HDAC) inhibitor,
for use in combination with bortezomib (Velcade) and
dexamethasone for treatment of patients with multiple
myeloma who have received at least 2...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
